Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers

Bettina Toth; Rienk Nieuwland; Susanne Liebhardt; Nina Ditsch; Kerstin Steinig; Petra Stieber; Andreas Rank; Peter Göhring; Christian J. Thaler; Klaus Friese; Ingo Bauerfeind

Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers

Bettina Toth
, Rienk Nieuwland
, Susanne Liebhardt
, Nina Ditsch
, Kerstin Steinig
, Petra Stieber
, Andreas Rank
, Peter Göhring
, Christian J. Thaler
, Klaus Friese
, Ingo Bauerfeind

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: The aim of the present prospective case-control study was to evaluate the putative relevance of circulating microparticles (MP) as a biomarker in breast cancer patients. MATERIALS AND METHODS: Endothelial cell-(EMP) and leukocyte-derived MP (LMP) were determined by flow cytometry in breast cancer patients (n = 41) and healthy controls (n = 25) and compared to carcinoembryonic antigen (CEA), cancer antigen (CA)15-3 and von Willebrand factor antigen (vWF) levels by specificity-sensitivity profiles. RESULTS: LMP, CEA and CA15-3 levels differed significantly between breast cancer patients and controls, whereas EMP and vWF did not. The specificity-sensitivity profiles of LMP and CA15-3 were similar. CONCLUSION: Increasing levels of circulating LMP (CD45+), CEA and CA15-3 correlated with increasing tumor size, thus reflecting disease stage. LMP showed an equal specificity-sensitivity profile to the established marker CA15-3 and therefore might have the potential to become a new biomarker in breast cancer patients

Original language	English
Pages (from-to)	1107-1112
Journal	Anticancer research
Volume	28
Issue number	2A
Publication status	Published - 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Cite this

@article{816a4dfd19944e4b9ac3ae140312e5dd,

title = "Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers",

abstract = "BACKGROUND: The aim of the present prospective case-control study was to evaluate the putative relevance of circulating microparticles (MP) as a biomarker in breast cancer patients. MATERIALS AND METHODS: Endothelial cell-(EMP) and leukocyte-derived MP (LMP) were determined by flow cytometry in breast cancer patients (n = 41) and healthy controls (n = 25) and compared to carcinoembryonic antigen (CEA), cancer antigen (CA)15-3 and von Willebrand factor antigen (vWF) levels by specificity-sensitivity profiles. RESULTS: LMP, CEA and CA15-3 levels differed significantly between breast cancer patients and controls, whereas EMP and vWF did not. The specificity-sensitivity profiles of LMP and CA15-3 were similar. CONCLUSION: Increasing levels of circulating LMP (CD45+), CEA and CA15-3 correlated with increasing tumor size, thus reflecting disease stage. LMP showed an equal specificity-sensitivity profile to the established marker CA15-3 and therefore might have the potential to become a new biomarker in breast cancer patients",

author = "Bettina Toth and Rienk Nieuwland and Susanne Liebhardt and Nina Ditsch and Kerstin Steinig and Petra Stieber and Andreas Rank and Peter G{\"o}hring and Thaler, \{Christian J.\} and Klaus Friese and Ingo Bauerfeind",

year = "2008",

language = "English",

volume = "28",

pages = "1107--1112",

journal = "Anticancer research",

issn = "0250-7005",

publisher = "International Institute of Anticancer Research",

number = "2A",

}

TY - JOUR

T1 - Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers

AU - Toth, Bettina

AU - Nieuwland, Rienk

AU - Liebhardt, Susanne

AU - Ditsch, Nina

AU - Steinig, Kerstin

AU - Stieber, Petra

AU - Rank, Andreas

AU - Göhring, Peter

AU - Thaler, Christian J.

AU - Friese, Klaus

AU - Bauerfeind, Ingo

PY - 2008

Y1 - 2008

N2 - BACKGROUND: The aim of the present prospective case-control study was to evaluate the putative relevance of circulating microparticles (MP) as a biomarker in breast cancer patients. MATERIALS AND METHODS: Endothelial cell-(EMP) and leukocyte-derived MP (LMP) were determined by flow cytometry in breast cancer patients (n = 41) and healthy controls (n = 25) and compared to carcinoembryonic antigen (CEA), cancer antigen (CA)15-3 and von Willebrand factor antigen (vWF) levels by specificity-sensitivity profiles. RESULTS: LMP, CEA and CA15-3 levels differed significantly between breast cancer patients and controls, whereas EMP and vWF did not. The specificity-sensitivity profiles of LMP and CA15-3 were similar. CONCLUSION: Increasing levels of circulating LMP (CD45+), CEA and CA15-3 correlated with increasing tumor size, thus reflecting disease stage. LMP showed an equal specificity-sensitivity profile to the established marker CA15-3 and therefore might have the potential to become a new biomarker in breast cancer patients

AB - BACKGROUND: The aim of the present prospective case-control study was to evaluate the putative relevance of circulating microparticles (MP) as a biomarker in breast cancer patients. MATERIALS AND METHODS: Endothelial cell-(EMP) and leukocyte-derived MP (LMP) were determined by flow cytometry in breast cancer patients (n = 41) and healthy controls (n = 25) and compared to carcinoembryonic antigen (CEA), cancer antigen (CA)15-3 and von Willebrand factor antigen (vWF) levels by specificity-sensitivity profiles. RESULTS: LMP, CEA and CA15-3 levels differed significantly between breast cancer patients and controls, whereas EMP and vWF did not. The specificity-sensitivity profiles of LMP and CA15-3 were similar. CONCLUSION: Increasing levels of circulating LMP (CD45+), CEA and CA15-3 correlated with increasing tumor size, thus reflecting disease stage. LMP showed an equal specificity-sensitivity profile to the established marker CA15-3 and therefore might have the potential to become a new biomarker in breast cancer patients

M3 - Article

C2 - 18507061

SN - 0250-7005

VL - 28

SP - 1107

EP - 1112

JO - Anticancer research

JF - Anticancer research

IS - 2A

ER -

Circulating microparticles in breast cancer patients: a comparative analysis with established biomarkers

Abstract

UN SDGs

Fingerprint

Cite this